A Two-Component regulatory system with opposite effects on glycopeptide antibiotic biosynthesis and resistance by Alduina R. et al.
1Scientific RepoRtS |         (2020) 10:6200  | https://doi.org/10.1038/s41598-020-63257-4
www.nature.com/scientificreports
A two-component regulatory 
system with opposite effects 
on glycopeptide antibiotic 
biosynthesis and resistance
Rosa Alduina1*, Arianna Tocchetti2, Salvatore costa1, clelia ferraro1, patrizia Cancemi1, 
Margherita Sosio2 & Stefano Donadio2
The glycopeptide A40926, produced by the actinomycete Nonomuraea gerenzanensis, is the precursor 
of dalbavancin, a second-generation glycopeptide antibiotic approved for clinical use in the USA and 
Europe in 2014 and 2015, respectively. The final product of the biosynthetic pathway is an O-acetylated 
form of A40926 (acA40926). Glycopeptide biosynthesis in N. gerenzanensis is dependent upon the 
dbv gene cluster that encodes, in addition to the two essential positive regulators Dbv3 and Dbv4, 
the putative members of a two-component signal transduction system, specifically the response 
regulator Dbv6 and the sensor kinase Dbv22. The aim of this work was to assign a role to these two 
genes. Our results demonstrate that deletion of dbv22 leads to an increased antibiotic production with 
a concomitant reduction in glycopeptide resistance. Deletion of dbv6 results in a similar phenotype, 
although the effects are not as strong as in the Δdbv22 mutant. Consistently, quantitative RT-PCR 
analysis showed that Dbv6 and Dbv22 negatively regulate the regulatory genes (dbv3 and dbv4), 
as well as some dbv biosynthetic genes (dbv23 and dbv24), whereas Dbv6 and Dbv22 positively 
regulate transcription of the single, cluster-associated resistance gene. Finally, we demonstrate that 
exogenously added acA40926 and its precursor A40926 can modulate transcription of dbv genes but 
with an opposite extent: A40926 strongly stimulates transcription of the Dbv6/Dbv22 target genes 
while acA40926 has a neutral or negative effect on transcription of those genes. We propose a model 
in which glycopeptide biosynthesis in N. gerenzanensis is modulated through a positive feedback by 
the biosynthetic precursor A40926 and a negative feedback by the final product acA40926. In addition 
to previously reported control systems, this sophisticated control loop might help the producing 
strain cope with the toxicity of its own product. This work, besides leading to improved glycopeptide 
producing strains, enlarges our knowledge on the regulation of glycopeptide biosynthesis in 
actinomycetes, setting N. gerenzanensis and its two-component system Dbv6-Dbv22 apart from other 
glycopeptide producers.
The glycopeptide antibiotic A40926 (Fig. 1A) is the precursor for dalbavancin (Fig. 1B), a semisynthetic lipo-
glycopeptide clinically used for treatment of acute skin infections caused by methicillin-susceptible and 
methicillin-resistant Staphylococcus aureus and Streptococcus pyogenes.
A40926 is produced by the actinomycete N. gerenzanensis as a complex of related compounds, differing 
mostly by the type of N-acyl chain attached to the glucuronic acid moiety. The core structure of A40926 con-
sists of a heptapeptide containing the proteinogenic amino acid tyrosine and the non-proteinogenic amino 
acids 3,5-dihydroxyphenylglycine (DPG) and 4-hydroxyphenylglycine (HPG). The heptapeptide is assembled 
by a nonribosomal peptide synthetase (NRPS) and modified by the action of various enzymes: four oxygen-
ases, one halogenase, one hydroxylase, two glycosyltransferases, one hexose oxidase, one methyltransferase, 
one N-deacetylase, one N-acyltransferase and one O-acetyltransferase1. The form with the acetylated mannose 
(acA40926) is considered the final biosynthetic product2. However, mild extraction conditions are necessary to 
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isolate acA40926. While A40926 and acA40926 are equipotent in antibacterial activity against most strains, the 
former is slightly more active against S. aureus and Neisseria gonorrhoeae3. Hence, the desacetylated form has 
been used as the substrate for dalbavancin semi-synthesis. In addition, as many methods for complex analysis 
involve alkaline treatment of the culture, which results in hydrolysis of the ester bond, past literature considered 
A40926 as the main fermentation product. Detailed studies of the regulation of glycopeptide biosynthesis in N. 
gerenzanensis will be crucial for the development of rational approaches towards overproduction of the dalba-
vancin precursor. The dbv gene cluster for acA40926 biosynthesis contains 37 protein-coding sequences (Fig. 1C) 
that participate in antibiotic biosynthesis, regulation, immunity, and export1,4. Specifically, the cluster encodes 
the positive regulators Dbv3 and Dbv4 that indirectly or directly activate different operons leading to acA40926 
biosynthesis5,6. Dbv3 and Dbv4 belong to the LAL (large ATP binding regulators of LuxR) and the StrR family 
of regulators, respectively. The cluster also contains the putative response regulator dbv6 and the sensor-kinase 
dbv22, whose products may be part of a two-component system (TCS), even if the genes are not organized in a 
bicistronic operon4,7. A relevant characterized TCS in actinomycetes is the Streptomyces coelicolor VanR (VanRsc) 
and VanS (VanSsc) system associated with a glycopeptide resistance cassette in this species, which however does 
not produce any glycopeptide.
Figure 1. Chemical structures of O-acetyl A40926 (A) and of dalbavancin (B) and genetic organization of 
the dbv cluster (C). (A,B). Only the component B0 (the major congener in the A40926 complex) is shown for 
simplicity. The acetyl group of A40926 and the chemical modification present in dalbavancin are indicated in 
red circle and pink, respectively. (C) The thin black arrows indicate experimentally determined operons. Red 
and green arrows represent the transcriptional units controlled by Dbv4 and Dbv3, respectively. The dbv genes 
are grouped by functional category as indicated. Asterisks indicate the genes analyzed by qRT-PCR analysis in 
the present work.
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In S. coelicolor, following vancomycin induction, the VanRSsc TCS activates transcription of the van-
HAX genes, leading to the synthesis of peptidoglycan precursors terminating with D-alanyl–D-lactate 
(DAla–D-Lac),  causing a 1000-fold decreased binding affinity of vancomycin to its target8–11. Thus, in its induc-
tion mechanism and in the resulting peptidoglycan modification, the mechanism leading to glycopeptide resist-
ance in S. coelicolor resembles that used by pathogenic Enterococcus spp12,13. While some glycopeptide producers 
do contain a vanHAX cassette, either associated with the gene cluster14–16 or elsewhere in the genome17, the N. 
gerenzanensis genome does not contain any such genes18. N. gerenzanensis must thus use different strategy(ies) to 
cope with the self-toxicity of its own product. Marcone and coworkers showed that the wild type strain synthe-
sizes a peptidoglycan with 3–3 cross-linked peptide stems using the carboxypeptidase Dbv719. Using substrates 
mimicking peptidoglycan, it was shown that Dbv7 cuts the D-Ala-D-Ala end of the peptidoglycan precursor on 
the outer surface of the cell membrane, mainly before and during antibiotic production19,20. However, deletion of 
dbv7 in the original host or its heterologous expression result in measurable but modest differences in glycopep-
tide resistance19.
In this study, we characterized the function of dbv6 and dbv22 with respect to glycopeptide biosynthesis and 
resistance in N. gerenzanensis and established that dbv biosynthesis genes are under negative control by this 
TCS, while the resistance gene dbv7 is under positive control. In addition, we discovered that exogenously added 
A40926 and acA40926 differently affect transcription of selected dbv genes. Based on the current results and those 
reported previously2, a complex model of regulation can be depicted with the late pathway intermediate A40926 
and the end product acA40926 having different roles in controlling antibiotic biosynthesis and resistance.
Results
Dbv6 and Dbv22 are transcriptional repressors of A40926 biosynthesis. N. gerenzanensis mutants 
defective in dbv6 and dbv22 were constructed as previously reported6 and as described under Material and 
Methods, respectively. When N. gerenzanensis was grown in a rich medium (RARE3) that affords good growth 
but moderate glycopeptide production, disruption of dbv6 or dbv22 did not significantly affect biomass accumu-
lation (Fig. 2A). Interestingly, bioassays (Fig. 2B) of culture broth collected along the growth showed that antibi-
otic production started at 54 h in both mutants (12 h earlier than in the parental strain) and proceeded to higher 
levels up to 96 h, the last analyzed time point. Liquid chromatography–mass spectrometry (LC-MS) analysis of 
96-h culture broths showed that the Δdbv6 and Δdbv22 mutants produced 52 and 70 µg/mL acA40926, respec-
tively, in comparison with 34 µg/mL, as observed with the parental strain.
When N. gerenzanensis was grown in a production medium (V40P), the higher production levels of the 
mutants were confirmed, with the Δdbv6 and Δdbv22 mutants producing 210 and 354 µg/mL acA40926 after 
Figure 2. Growth curves and antibiotic production by N. gerenzanensis wild type, Δdbv6 and Δdbv22 strains 
in RARE3 medium. (A) The dry weight of the wild type, Δdbv6 and Δdbv22 strains are shown with green, red 
and blue lines, respectively. Standard deviation was calculated as average of three technical and two biological 
replicates. (B) Bioassays of 50 µL of the culture broth of the wild type, Δdbv6 and Δdbv22 strains using K. 
rhizophila as test strain. (+) and (−) indicate the positive (culture broth collected from the parental strain after 
120 h) and negative (only growth medium) control, respectively.
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7 days, respectively, in comparison with 130 µg/mL seen in the parental strain (Fig. 3). Interestingly, under these 
conditions, we observed a small but consistent decrease in biomass accumulation, which was inversely related to 
the amount of produced glycopeptide. There was no difference in complex composition between the mutants and 
the wild type (Supplementary Fig. S1), with acA40926 as the main product at all time points in the three strains.
These results demonstrate that Dbv6 and Dbv22 negatively regulate glycopeptide production and their aboli-
tion leads to increased antibiotic production, despite a small decrease in biomass, indicating a substantial higher 
productivity of the mutants (in terms of µg of product per unit of biomass) in comparison to the parental strain. 
Across two different media, deletion of dbv22 has a more prominent effect than dbv6.
Quantitative RT-PCR (qRT-PCR) analysis after 54 h of growth in RARE3 medium of the wild type and the two 
mutants was carried out to identify the Dbv6/Dbv22 target genes within the dbv cluster (Fig. 4). We focused our 
attention on ten genes as representatives of all the dbv operons. Besides the regulators dbv3, dbv4 and dbv6, the 
analysis was carried out on the biosynthetic genes dbv1 and dbv5 (HPG synthesis), dbv23 (mannose acetylation) 
and dbv15 (MbtH-like protein assisting NRPS action), on the ABC-transporter genes dbv18, and dbv24, and on 
the resistance gene dbv75,21 (Fig. 1C). Consistent with the results from bioassays and LC-MS analysis, qRT-PCR 
analysis showed that transcription of some analyzed genes was strongly influenced by deletion of dbv6 and more 
so by dbv22 genes (Fig. 4). Indeed, the transcriptional levels of dbv3, dbv4, dbv5, dbv23 and dbv24 increased 
approximately 2–5 fold in the Δdbv6 mutant and 5–20 fold in the Δdbv22 mutant; in contrast, dbv7 was appar-
ently not transcribed in both mutants. The transcriptional levels of dbv1, dbv6, and dbv18 were not influenced by 
either mutation (Fig. 4).
Dbv22 enhances glycopeptide resistance. We tested the wild type and the two mutant strains for sensi-
tivity to A40926 and acA40926. Consistent with previous results19, the wild type strain formed no visible colonies 
when plated on medium containing 4 µg/mL A40926. Remarkably, it was more sensitive to acA40926 than to its 
Figure 3. AcA40926 production and growth in V40P medium of the wild type, Δdbv6 and Δdbv22 strains. 
Squares indicate acA40926 concentrations, while triangles represent %PMV. Brown, red and violet symbols 
correspond to the wild type, Δdbv6 and Δdbv22 strains, respectively.
Figure 4. qRT-PCR of dbv genes in the wild type and Δdbv6 and Δdbv22 mutant strains. For each gene, data 
are normalized to the parental strain (blue bars). Red and green bars represent relative RNA levels seen in the 
Δdbv6 and Δdbv22 strains, respectively. Error bars are calculated from three independent determinations of 
mRNA abundance in each sample. RNAs were extracted after 54 h of growth in RARE3 medium.
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desacetylated precursor, with a significant reduction in the ability to form colonies observed already at 0.5–1 µg/
mL (Fig. 5). No significant differences between the wild type and the Δdbv6 mutant were observed. In contrast, 
the Δdbv22 mutant strain was more sensitive to acA40926 and A40926, and it was able to form visible colonies 
only with up to 0.5 and 0.2 µg/mL of A40926 and acA40926, respectively (Fig. 5). Thus, consistent with qRT-PCR 
analysis, Dbv22 positively controls resistance to glycopeptides, likely by regulating expression of the carboxy-
peptidase Dbv7. The lack of an effect on glycopeptide resistance by the dbv6 deletion might be due to the narrow 
range of glycopeptide concentration in which an effect is seen.
A40926 strongly induces expression of dbv genes. The above results indicate that N. gerenzanensis can 
discriminate, in terms of sensitivity, between the highly related glycopeptides A40926 and acA40926. Previous 
work had also indicated that exogenously added acA40926, but not its desacetylated form, had an inhibitory effect 
on glycopeptide production2. We thus wondered whether exogenously added glycopeptides would have any effect 
on the transcriptional levels of the Dbv6/Dbv22 target genes. To this end, a 24 h culture of the parental strain 
inV40P medium was equally divided into three flasks, with each flask receiving either 0.5 µg/mL A40926, 0.5 µg/
mL acA40926 or no addition. After further 2- and 5-h incubation, RNA was extracted and the transcriptional 
levels of all the regulatory genes (dbv3, dbv4 and dbv6) and of the Dbv6-targeted genes (dbv7, dbv23 and dbv24) 
were analyzed by qRT-PCR (Fig. 6). Addition of acA40926 had a modest inducing effect on the expression of the 
regulatory genes dbv4 and dbv6, the resistance gene dbv7 and the acetyltransferase gene dbv23, but only 2 h after 
compound addition. After 5 h, genes were slightly repressed (dbv3, dbv4, dbv6 and dbv7) or unaffected (dbv23 and 
Figure 5. Resistance assay of the wild type and Δdbv6 and Δdbv22 mutant strains. Plating efficiency of the wild 
type, Δdbv6 and Δdbv22 strains on different concentrations of A40926 (solid lines) or of acA40926 (dashed 
lines). Reported data are the average of two independent counts. The limit of detection were 105 CFU/mL for the 
wild type, Δdbv6, and Δdbv22 strains.
Figure 6. qRT-PCR analysis of the gene expression of dbv3, dbv4, dbv6, dbv7, dbv23 and dbv24 in the wild type 
strain. RNA was isolated from the wild type strain incubated in V40P medium for 2 and 5 h in the presence of 
0.5 µg/mL A40926 (black bars) or 0.5 µg/mL acA40926 (red bars). Data are expressed as relative values to the 
no-addition controls. Within each sample, mRNA levels were normalized to hrdB, arbitrarily setting the ratio 
for each sample to 1. Standard deviations are calculated from three independent determinations of mRNA 
abundance in each sample.
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dbv24). In contrast, addition of A40926 did not significantly affect transcription levels after 2 h. However, after 5 h 
all the analyzed genes were induced, with transcription levels 2-fold (for dbv3), 3–6-fold (for dbv4, dbv6 and dbv7) 
or 13–14-fold (for dbv23 and dbv24) higher relative to uninduced cells. qRT-PCR of the analyzed dbv genes in all 
three cultures before induction indicated modest flask-to-flask variation (Supplementary Fig. S2).
The above experiments were performed using the wild type strain, which does produce acA40926 and related 
pathway intermediates, with exogenous compounds added during early exponential growth, when glycopeptide 
levels are below the limit of detection (about 1 µg/mL). When a similar experiment was carried out with the 
Δdbv4 mutant strain, which does not produce any glycopeptide6, we could not detect any transcription of dbv23 
and dbv24, suggesting that these genes might be indirect targets of Dbv4 (Supplementary Fig. S3). Thus, one or 
more components of the glycopeptide complex or intermediates thereof could exert a positive feedback on the 
transcription of at least some dbv genes.
Direct control of Dbv6 on dbv4 and dbv7 gene expression. We investigated whether Dbv6 can bind 
to the upstream region of the target genes and directly control their expression. Gel mobility shift assays of the 
regions upstream to dbv3, dbv4, dbv6, dbv7, dbv23 and dbv24 were carried out using a purified His-tagged Dbv6 
protein overexpressed in E. coli. These assays did reveal a binding activity of Dbv6 towards the upstream regions 
of the regulatory genes dbv3 and dbv4, of the resistance gene dbv7, of the genes dbv23-dbv22, coding for the 
acetyltransferase and the sensor kinase, and of the operon dbv24-dbv28, which encodes an ABC-transporter, 
two NRPS modules, the N-methyltransferase and the enzyme involved in β-hydroxylation of the tyrosine residue 
(Fig. 7). No shift was detected using the upstream region of dbv6 (Fig. 7). Control experiments using the internal 
region of the vegetative sigma factor encoding gene (Supplementary Fig. S4) further confirmed the specificity of 
Figure 7. Gel mobility shift assays of DNA regions upstream of dbv3, dbv4, dbv7, dbv23, dbv24 and dbv6. Lanes 
labeled with an asterisk contained the probe only (updbv3, updbv4, updbv7, updbv23, updbv24 and updbv6). All 
lanes contained 50 ng of target DNA. Increasing concentrations of His-Dbv6 (0.5, 1, 1.5, 2 mM) were incubated 
in the presence of probes as indicated.
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DNA binding by Dbv6 observed on some of the target genes. Thus, these data are consistent with Dbv6 directly 
controlling expression of the target genes. Further studies will be necessary to understand how Dbv6 exerts posi-
tive and negative control on different DNA regions.
Dbv6 and Dbv22 are unrelated to other TCSs associated with other glycopeptide gene clusters. 
TCSs are often associated with glycopeptide gene clusters, where they have been shown in some cases to play a 
role in glycopeptide resistance. They appear similar to the well-characterized S. coelicolor VanRS system, which 
plays a role in glycopeptide resistance in a non-producing strain9. However, reciprocal Blast searches indicate that 
Dbv6 and Dbv22 are not orthologs of VanRsc and VanSsc, respectively. Inspired by recent work on phylogenetic 
analysis of cluster-associated StrR- and LuxR-related regulators22, we performed a phylogenetic analysis of TCSs 
from actinomycetes. To this end, we retrieved response regulators and sensory kinases associated with char-
acterized actinobacterial gene clusters from the MiBIG database23, well-characterized TCSs from Streptomyces 
coelicolor24,25 and the response regulators and sensory kinases identified in the N. gerenzanensis genome18 (Fig. 8).
With respect to the response regulators, those associated with the balhimycin, teicoplanin and A47934 clusters 
branch together along with S. coelicolor VanR (Fig. 7, left panel). In contrast, Dbv6 clusters together with response 
Figure 8. Phylogenetic analysis of 62 response regulators (left panel) and 65 sensory kinases (right panel). 
Sequences associated with established gene clusters are identified by the compound name followed by the 
genus of the corresponding strain; characterized S. coelicolor proteins are identified by the protein name 
followed by the SCO code; and N. gerenzanensis sequences are denoted by the SBO or SBP codes. The branches 
associated with the Van-and Dbv-related TCSs are identified by green and orange boxes, respectively. Green 
and red arrows indicate the adjacent members of two different, uncharacterized N. gerenzanensis TCSs closely 
associated with the Dbv branches. Sequences associated with N. gerenzanensis biosynthetic gene clusters, as 
identified by AntiSMASH 5.042, have a yellow highlight.
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regulators associated with gene clusters for kistamicin A (from a Nonomuraea sp26) and for feglymycin (from a 
Streptomyces sp27.). Kistamicin A is a partially cross-linked heptapeptide sharing some amino acid residues with 
glycopeptide antibiotics, whereas feglymycin is a linear tridecapeptide containing several HPG and DPG resi-
dues. Both compounds have antiviral activity but modest antibacterial activity in comparison with glycopeptide 
antibiotics28–30.
A similar picture emerges when analyzing the sensory kinases: those associated with the balhimycin, teicopla-
nin and A47934 clusters, and S. coelicolor VanS form a separate branch from the one containing Dbv22 and the 
kistamicin A- and flegymycin-associated sequences (Fig. 8, right panel). Interestingly, the adjacent members of 
two different, uncharacterized TCSs encoded by the N. gerenzanensis genome cluster closely with the Dbv6 and 
Dbv22 branches, suggesting these proteins might respond to similar stimuli and/or be regulated by similar fac-
tors. It should be noted that all the other sensory kinases or response regulators from N. gerenzanensis associated 
to a putative biosynthetic gene cluster are unrelated to Dbv6 or Dbv22.
Discussion
The results presented here provide evidence that the response regulator Dbv6 and the sensor kinase Dbv22 neg-
atively control A40926 production and that Dbv22 positively controls A40926 resistance. These effects are asso-
ciated with altered transcription levels. Indeed, strains deleted for these genes are upregulated in the expression 
of the two key regulators dbv3 and dbv4. Conversely, the Δdbv22 mutant strain expresses less dbv7, the only 
resistance gene present in the dbv cluster. This would suggest that Dbv6 and Dbv22 represent the two compo-
nents of a signal transduction system responding to some stimuli and controlling key elements of the dbv cluster. 
Remarkably, deletion of dbv22 can lead to the paradoxical result of a mutant producing increased glycopeptide 
levels while becoming more sensitive to its own product.
While TCSs are frequently found in glycopeptide gene clusters, different regulatory strategies are apparently 
adopted by glycopeptide-producing actinomycetes. Abolition of the response regulator or of the sensor kinase 
gene in Streptomyces toyocaensis led to increased sensitivity to A4793411. In Amycolatopsis balhimycina, the dele-
tion of genes for the VanRS-like TCS VnlRSAb affected VanY expression in a ΔvanHAX background31 while did 
not influence balhimycin production17,31. In the glycopeptide non-producing S. coelicolor, deletion of vanR but 
not of vanS led to a strain sensitive to vancomycin11. Apart from the VanR genes associated with a vanHAX resist-
ance cassette (e.g, those from S. coelicolor, S. toyocaensis and Actinoplanes teichomyceticus), the gene(s) targeted by 
VanR in A. balhimycina remain to be identified. Here, we demonstrate that in N. gerenzanensis direct target genes 
of Dbv6 are the regulatory genes dbv3 and dbv4, and the genes dbv23-dbv22, coding for the acetyltransferase and 
the sensor kinase, and the dbv24-dbv28 operon, since the transcription of all these genes is induced in the Δdbv6 
mutant background and that Dbv6 binds to the upstream regions of these genes. Another direct target of Dbv6 
but regulated in the opposite manner is the peptidase dbv7 (Fig. 7).
The impacts of the dbv6 and dbv22 mutations are quantitatively different. First of all, the relative expression 
levels of the analyzed dbv genes (encoding the positive regulators Dbv3 and Dbv4, the prephenate dehydrogenase 
Dbv5, the acetyltransferase Dbv23 and the ABC-transported Dbv24) in the Δdbv6 mutant are somehow inter-
mediate between those of the parental strain and of the Δdbv22 mutant (Fig. 4). In terms of antibiotic resistance, 
the Δdbv22 strain is marginally but consistently more sensitive than the parental strain and the Δdbv6 mutant 
to A40926 and acA40926. Finally, when N. gerenzanensis is grown in production medium, the Δdbv6 and the 
Δdbv22 mutants show, up to 48 h, an identical but slightly higher acA40926 production rate than the parental 
strain, with Δdbv22 keeping an equivalent rate up to 7 days and reaching acA40926 levels (350 µg/mL) signifi-
cantly higher than Δdbv6 and the parental strain (200 and 130 µg/mL, respectively; Fig. 3). Remarkably, higher 
production levels by Δdbv22 are achieved despite a slightly lower biomass accumulation (Fig. 3).




Nonomuraea gerenzanensis Wild type ATCC 39727
Δdbv6 mutant N. gerenzanensis strain in which the dbv6 gene was replaced with an apramycin cassette
6
Δdbv22 mutant N. gerenzanensis strain in which the dbv22 gene was replaced with an apramycin cassette This study
Kocuria rhizophila Used for bioassay of A40926 ATCC 9341
Escherichia coli DH10B F_ endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 Δ80lacZΔM15 araD139 Δ(ara-leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ-; host for routine subcloning experiments Invitrogen
Escherichia coli ET12567/pUZ8002 (dam-13::Tn9 dcm-6) pUZ8002
+(ΔoriT); used for conjugative transfer of DNA and 
for demethylating plasmid DNA
44
Escherichia coli BW25113/pIJ790 Δ (araD-araB)567 ΔlacZ4787 (::rrnB-4) lacIp-4000 (lacIq) λ
- rpoS369 (Am) rph-1 
Δ (rhaD-rhaB) 568 hsdR514: used to generate recombinant cosmid 1B1
45
Plasmid/cosmid
1B1 Cosmid containing part of the dbv cluster from dbv17 to dbv37 4
1B1Δdbv22 Derivative of 1B1 with the inactivated dbv22 gene This study
pIJ773 pUC19 containing the aac(3)IV-oriT cassette; source of the aac(3) gene 37
Table 1. Bacterial strains, plasmids and cosmids used in this study.
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The fact that all the analyzed parameters are more strongly altered in the Δdbv22 than in the Δdbv6 back-
ground suggests that Dbv22 and/or Dbv6 might interact with other response regulators and/or sensor kinases, 
respectively, present in the cell. Indeed, the N. gerenzanensis genome harbors 43 and 47 TCS pairs, some of them 
highly related to VanR and VanS (Fig. 8). A homologous of dbv6 gene is present in the N. gerenzanensis genome. 
The gene is located about 4.5 Mbp away from Dbv6, with which it shows 68% sequence identity and 77% simi-
larity. All 8 diagnostic residues of the phosphorylation site are invariant with Dbv6. The HTH domain is highly 
conserved.
Marcone and coworkers19 have previously shown that N. gerenzanensis is essentially sensitive to A40926, that 
the carboxypeptidase VanY (i.e., Dbv7) provides some protection but that insensitivity to glycopeptides is mostly 
acquired during growth by some unknown mechanism. That some other resistance mechanism operates in N. 
gerenzanensis is consistent with our observed lack of transcription of dbv7 in the Δdbv6 strain (Fig. 4), a mutant 
that is as glycopeptide resistant as the parental strain (Fig. 5). Thus, dbv6 does not apparently contribute to glyco-
peptide resistance while dbv22 does, suggesting that a second resistance mechanism influenced by Dbv22 takes 
over. The complex interplay of glycopeptide production and resistance is also highlighted by the fact that deletion 
of dbv7 did not affect A40926 production, as reported by Marcone and coworkers19.
When added just at 24 h of growth, when no glycopeptide production is detected yet, 0.5 µg/mL A40926 can 
strongly induce expression of all tested dbv genes, particularly dbv23 and dbv24. AcA40926 has the opposite 
effect. The simplest explanation of this observation is that A40926, but not acA40926, binds to a receptor to 
activate signal transduction, relieving inhibition or leading to a massive transcription of dbv genes. It is tempting 
to speculate that the receptor that A40926 binds to is actually Dbv22. Indeed, the ~14-fold stimulation of dbv24 
upon A40926 addition is remarkably similar to its upregulated expression in the Δdbv22 background. Sensor 
kinases have been shown to be able to recognize and respond to glycopeptides: VanSsc is induced by vancomycin 
but not by teicoplanin and A479348,11, while the S. toyocaensis VanS sensor kinase is induced by A47934 but not 
by vancomycin and teicoplanin11.
In earlier work, we showed that a strain defective in mannose acetylation produces increased levels of A40926 
in comparison to the wild type and that this enhanced production can be reverted by adding acA40926 – but not 
A40926 – to the culture at time zero, while addition of acA40926 had no effect on the wild type2. The present and 
previous results are consistent assuming that acA40926 can also bind to the same receptor but it cannot trigger its 
activation. Thus, acA40926 would compete with A40926 for the same binding site, acting as an apparent inhibitor 
of glycopeptide production. Discrimination between the acetylated and desacetylated form of the glycopeptide 
by N. gerenzanensis can also be observed in the resistance profile of the wild type, which is more sensitive to 
acA40926 than A40926 (Fig. 5).
The data presented here and in previous work2,5,6 allow us to refine a possible model for regulation of gly-
copeptide production in N. gerenzanensis1. When cells are actively growing, transcription of dbv3 and dbv4 is 
repressed by the direct action of Dbv6, as well as by other factors related to growth (nutritional factors, or quorum 
sensing systems could control A40926 biosynthesis)5. At the same time, the resistance gene dbv7 is expressed as 
a safeguard mechanism against small amounts of glycopeptides that might be produced. As growth slows down, 
expression of the master regulators Dbv3 and Dbv4 increases so that some glycopeptide synthesis can occur. 
When sufficient A40926 accumulates, repression mediated by Dbv6/Dbv22 is relieved and further expression of 
the dbv genes can occur, including that of the acetyltransferase dbv23 and of the ABC transporter dbv24, which 
results in formation of acA40926 form and its export outside of the cell, where it can compete out A40926 for 
Dbv22 binding, eventually restoring repression exerted by Dbv6/Dbv22.
This mechanism is somehow reminiscent of the feed forward mechanism proposed for microbisporicin/NAI-
107 production in Microbispora corallina, where a late pathway intermediate can activate production32 through 
Gene(s) Forward (5′-3′) Reverse (5′-3′) Predicted size (bp)
Used in RT-PCR or qRT-PCR
hrdb ctgatcaacaaggtcgcccg gccgtacctctgcacctcg 129
16S agcttgttggtggggtagtg tcaccgctacaccaggaatt 470
dbv3 gaagaggttgcccaggtcac ccgaggcgctctacatcac 101
dbv4 cagtaattccggcttggtcc aaacaggtcggcatctccc 114
dbv5 gtggacctggcattgatcg ctggtcacatcggtgtacgc 101
dbv6 agctgtgcgctgagatcg acggcttcggcagatagtc 126
dbv7 ccagctcgtcggtctcac cccttgacgtggttggac 141
dbv23 gaccgcccacttgttgatc ggcagctcaccacctacg 110
dbv24 tcggaggtttgctgaagg agatcgaatccaatgcgg 147
Used to prepare probes for EMSA
upstream 3 gaatcgagcaacctcgtcag gcaggaatgggaaaggatct 300
upstream 4 gcatcggtcttatccgaaac cgtcgcatcctcttttcttc 226
upstream 6 tggtcgaggtctccgtgc cattcgtgtcgccgtctc 150
upstream 7 tgaaggcgacgatcaacc tcctcatccctctcctccag 188
upstream 23 gtccaggtgaacgcttggt ccttcagcaaacctccgaac 178
upstream 24 gcaggtcggaagggacatc gtgaccaagcgttcacctgg 176
Table 2. Primers used in this study.
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the activation of the ECF sigma factor σMibX, sequestered at the membrane level by an antisigma factor. An 
unknown signal should lead to production of microbisporicin, the inactivation of the anti-sigma factor, the 
release of σMibX, and high-level expression of the entire gene cluster. Interestingly, both A40926 and NAI-107 
target lipid II33, are produced by two strains belonging to different genera of the order Streptosporangiales that 
contain 3–3 cross-linked dimers in their cell wall and that are highly sensitive to their own product33.
Material and methods
Bacterial strains and culture conditions. The bacterial strains and plasmids used in this study are listed 
in Table 1. Escherichia coli strains were grown in Luria broth liquid medium at 37 °C and supplemented with 
50 µg/mL apramycin when necessary to maintain plasmids.
Cell stocks of the N. gerenzanensis strains were prepared from cultures in RARE3 medium as already 
described34 and stored at −80 °C. Liquid cultures were prepared by inoculating 0.2 mL of the frozen stock into 
20 mL of RARE3 medium; after 120 h of growth, 1 mL of this culture was inoculated into 50 mL of fresh RARE3 
medium in an orbital shaker (500 × g) in 250-mL baffled flasks at 30 °C. To detect glycopeptide production, sam-
ples of culture broths at different time points were withdrawn and stored at −80 °C before analysis. Cultivation in 
glycopeptide production medium was performed as already described2. Biomass was determined by measuring 
the cell dry weight of mycelial pellet recovered from a 1-mL culture sample after drying the pellet at 65 °C for 
about 24 h. Alternatively, the relative packed mycelial volume (%PMV) was determined after centrifugation of a 
6-mL culture sample for 10 min at 4000 × g.
For assessing induction by glycopeptides, the parental strain or the Δdbv4 mutant were cultivated in V40S 
medium as above and then transferred into (fresh) V40P medium2. After 24 h at 30 °C, the culture was equally 
divided into three flasks, and either 0.5 µg/mL A40926 or 0.5 µg/mL acA40926 were added, with the third flask 
used as no-addition control. After further 2 and 5 h, 1-mL samples were collected and centrifuged to recover cells. 
RNA was extracted and processed as below.
Analysis of antibiotic production. Antibiotic production of the mutant strains was firstly evaluated using 
the paper disc diffusion method and Kocuria rhizophila as the assay organism as described previously35. For 
high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) 
analyses, 500 µL aliquots of broth cultures were collected at the time points indicated and treated as reported 
previously6,36.
Construction of the Δdbv22 strain. PCR targeting37 was applied to replace dbv22 with a cassette con-
taining an apramycin-selectable marker using pIJ773 as template and the PCR primers reported in Table 2. E. coli 
BW25113/pIJ790 bearing cosmid 1B14 was electrotransformed with the deletion cassette. Intergeneric conjuga-
tion was carried out as previously reported6. Exconjugants were analyzed by PCR (Supplementary Fig. S5) using 
primers reported in Table 2. One out of eleven clones analyzed contained the interrupted dbv22 gene and used 
for further studies. Sequencing of the PCR product confirmed that the apramycin-resistant cassette was correctly 
inserted in the target gene through homologous double-cross recombination.
Resistance assay. The ability to form colonies of the N. gerenzanensis wild type, Δdbv6 and Δdbv22 strains 
was assessed by plating serial dilutions of stock cultures (prepared from frozen mycelium) on 0.25X BTT plates38 
containing 0, 0.1, 0.2, 0.5, 1.0, 2.0 or 4.0 µg/mL A40926 or acA40926. Two replicate plates were used for each anti-
biotic concentration. After 6 days at 30 °C, the number of colony forming units (CFU) was recorded.
Total RNA isolation and qRT-PCR analysis. To perform transcriptional analysis, a 6-mL sample was 
withdrawn from a 30-mL culture. The mycelium was harvested by centrifugation and RNA was extracted using 
the RNeasy midi kit (Qiagen), followed by treatment with DNase I (Roche) according to the manufacturer’s 
instructions. RNA quality was previously checked using Reverse transcription (RT)-PCR analysis as previously 
described39. It was converted to cDNA as already described34 and amplified using primers reported in Table 2. 
As control genes, hrdB, encoding a vegetative sigma factor, or 16S rRNA, were used. Gene expression was ana-
lyzed quantitatively by using the 7300 real-time PCR system (Applied Biosystems) with SYBR green PCR master 
mix (Applied Biosystems) in 96-well plates. Two microliters of cDNA was added to 20 µL of the PCR mixture. 
Amplification required activation of AmpErase UNG at 50 °C for 2 min, followed by denaturation at 95 °C for 
10 min and then 40 cycles at 95 °C for 15 s and 60 °C for 1 min.
Overexpression and purification of recombinant protein His-Dbv6. Escherichia coli DH10B 
and BL21 (Invitrogen) were used in this study. Plasmids pGEM-T (Promega) and pRSETB (Invitrogen) were 
used for cloning PCR products, and protein expression, respectively. N. gerenzanensis chromosomal DNA 
was used as template to amplify dbv6 by PCR using the primers 5’-aaaaggatccaatgcgcgttctggtggtgga-3’ and 
5’-ttttaagctttcagatgcgatatccctcgc-3’ (underlines indicate the BamHI and HindIII sites, respectively). The amplified 
fragment was digested with BamHI plus HindIII and ligated into the BamHI and HindIII sites of pRSETB, yielding 
pRSET-Dbv6, which was introduced into BL21(DE3)pLysS cells by heat shock treatment40. Plasmid pRSET-Dbv6 
expresses the entire Dbv6 protein with a His6 tag at its N terminus under the control of the T7 promoter and the 
lac operator. Fidelity of PCR amplification was confirmed by DNA sequencing. Dbv6 overexpression and purifi-
cation were performed using the procedures already described for Dbv45.
Gel mobility shift assay. The gel mobility shift assay was performed according to the method already 
described41. Briefly, for the binding assay, increasing amount of Dbv6 (2.8 to 14 µg) was incubated for 10 min 
at 4 °C in 20 μL of 12.5 mM Tris-HCl (pH 7.5), 10% glycerol, 62.5 mM KCl, 0.75 mM DTT, and 5 mM MgCl2. 
After 15 min of incubation with 100 ng of DNA, complexes and free DNA were resolved on non-denaturing 5% 
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polyacrylamide gels run in 0.5× Tris-borate-EDTA buffer at 150 V for approximately 2 h and then stained in a 
bath containing ethidium bromide. The DNA probes were amplified by PCR using the primers listed in Table 2. 
BSA and the internal region of hrdB were used in control experiment (Supplementary Fig. 4).
Phylogenetic analysis. Thirteen response regulators and ten sensory kinases were retrieved from the 
MiBIG database of characterized actinobacterial biosynthetic gene clusters23; and forty-one response regulators 
and forty-seven sensory kinases were identified by blast searches of the N. gerenzanensis genome18. Seven charac-
terized TCSs from S. coelicolor (AbsA, Afs, Dra, Glu, Osd, Pho and Van)24,25 were also included. Sequences associ-
ated with N. gerenzanensis biosynthetic gene clusters were identified by AntiSMASH 5.042. Sequence alignments 
and phylogenetic analyses were performed with the MEGA 7 package43.
Received: 20 November 2019; Accepted: 3 March 2020;
Published: xx xx xxxx
References
 1. Alduina, R., Sosio, M. & Donadio, S. Complex Regulatory Networks Governing Production of the Glycopeptide A40926. Antibiotics 
7, https://doi.org/10.3390/antibiotics7020030 (2018).
 2. Sosio, M., Canavesi, A., Stinchi, S. & Donadio, S. Improved production of A40926 by Nonomuraea sp. through deletion of a 
pathway-specific acetyltransferase. Applied microbiology and biotechnology 87, 1633–1638, https://doi.org/10.1007/s00253-010-
2579-2 (2010).
 3. Goldstein, B. P. et al. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrobial agents and chemotherapy 31, 
1961–1966 (1987).
 4. Sosio, M., Stinchi, S., Beltrametti, F., Lazzarini, A. & Donadio, S. The gene cluster for the biosynthesis of the glycopeptide antibiotic 
A40926 by nonomuraea species. Chem Biol 10, 541–549 (2003).
 5. Alduina, R. et al. Phosphate-controlled regulator for the biosynthesis of the dalbavancin precursor A40926. Journal of bacteriology 
189, 8120–8129, https://doi.org/10.1128/JB.01247-07 (2007).
 6. Lo Grasso, L. et al. Two Master Switch Regulators Trigger A40926 Biosynthesis in Nonomuraea sp. Strain ATCC 39727. Journal of 
bacteriology 197, 2536–2544, https://doi.org/10.1128/JB.00262-15 (2015).
 7. Donadio, S., Sosio, M., Stegmann, E., Weber, T. & Wohlleben, W. Comparative analysis and insights into the evolution of gene 
clusters for glycopeptide antibiotic biosynthesis. Molecular genetics and genomics: MGG 274, 40–50, https://doi.org/10.1007/s00438-
005-1156-3 (2005).
 8. Hong, H. J. et al. Characterization of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a novel gene 
(vanK) required for drug resistance. Molecular microbiology 52, 1107–1121, https://doi.org/10.1111/j.1365-2958.2004.04032.x 
(2004).
 9. Hutchings, M. I., Hong, H. J. & Buttner, M. J. The vancomycin resistance VanRS two-component signal transduction system of 
Streptomyces coelicolor. Molecular microbiology 59, 923–935, https://doi.org/10.1111/j.1365-2958.2005.04953.x (2006).
 10. Hong, H. J., Hutchings, M. I. & Buttner, M. J. Biotechnology & Biological Sciences Research Council, U. K. Vancomycin resistance 
VanS/VanR two-component systems. Advances in experimental medicine and biology 631, 200–213, https://doi.org/10.1007/978-0-
387-78885-2_14 (2008).
 11. Novotna, G. B., Kwun, M. J. & Hong, H. J. In Vivo Characterization of the Activation and Interaction of the VanR-VanS Two-
Component Regulatory System Controlling Glycopeptide Antibiotic Resistance in Two Related Streptomyces Species. Antimicrobial 
agents and chemotherapy 60, 1627–1637, https://doi.org/10.1128/AAC.01367-15 (2015).
 12. Haldimann, A., Fisher, S. L., Daniels, L. L., Walsh, C. T. & Wanner, B. L. Transcriptional regulation of the Enterococcus faecium 
BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12. Journal 
of bacteriology 179, 5903–5913, https://doi.org/10.1128/jb.179.18.5903-5913.1997 (1997).
 13. Arthur, M., Molinas, C. & Courvalin, P. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide 
peptidoglycan precursors in Enterococcus faecium BM4147. Journal of bacteriology 174, 2582–2591, https://doi.org/10.1128/
jb.174.8.2582-2591.1992 (1992).
 14. Sosio, M. et al. Organization of the teicoplanin gene cluster in Actinoplanes teichomyceticus. Microbiology 150, 95–102, https://doi.
org/10.1099/mic.0.26507-0 (2004).
 15. Li, T. L. et al. Biosynthetic gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and 
the key acyltransferase. Chem Biol 11, 107–119, https://doi.org/10.1016/j.chembiol.2004.01.001 (2004).
 16. Pootoolal, J. et al. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from Streptomyces toyocaensis 
NRRL15009. Proc Natl Acad Sci USA 99, 8962–8967, https://doi.org/10.1073/pnas.102285099 (2002).
 17. Schaberle, T. F. et al. Self-resistance and cell wall composition in the glycopeptide producer Amycolatopsis balhimycina. 
Antimicrobial agents and chemotherapy 55, 4283–4289, https://doi.org/10.1128/AAC.01372-10 (2011).
 18. D’Argenio, V. et al. The complete 12 Mb genome and transcriptome of Nonomuraea gerenzanensis with new insights into its 
duplicated “magic” RNA polymerase. Scientific reports 6, 18, https://doi.org/10.1038/s41598-016-0025-0 (2016).
 19. Marcone, G. L. et al. Novel mechanism of glycopeptide resistance in the A40926 producer Nonomuraea sp. ATCC 39727. 
Antimicrobial agents and chemotherapy 54, 2465–2472, https://doi.org/10.1128/AAC.00106-10 (2010).
 20. Binda, E., Marcone, G. L., Pollegioni, L. & Marinelli, F. Characterization of VanYn, a novel D,D-peptidase/D,D-carboxypeptidase 
involved in glycopeptide antibiotic resistance in Nonomuraea sp. ATCC 39727. The FEBS journal 279, 3203–3213, https://doi.
org/10.1111/j.1742-4658.2012.08706.x (2012).
 21. Sosio, M., Bossi, E., Bianchi, A. & Donadio, S. Multiple peptide synthetase gene clusters in Actinomycetes. Molecular & general 
genetics: MGG 264, 213–221, https://doi.org/10.1007/s004380000336 (2000).
 22. Yushchuk, O. et al. Regulation of teicoplanin biosynthesis: refining the roles of tei cluster-situated regulatory genes. Applied 
microbiology and biotechnology 103, 4089–4102, https://doi.org/10.1007/s00253-019-09789-w (2019).
 23. Medema, M. H. et al. Minimum Information about a Biosynthetic Gene cluster. Nat Chem Biol 11, 625–631, https://doi.org/10.1038/
nchembio.1890 (2015).
 24. van der Heul, H. U., Bilyk, B. L., McDowall, K. J., Seipke, R. F. & van Wezel, G. P. Regulation of antibiotic production in 
Actinobacteria: new perspectives from the post-genomic era. Natural product reports 35, 575–604, https://doi.org/10.1039/
c8np00012c (2018).
 25. Daniel-Ivad, M., Pimentel-Elardo, S. & Nodwell, J. R. Control of Specialized Metabolism by Signaling and Transcriptional 
Regulation: Opportunities for New Platforms for Drug Discovery? Annual review of microbiology 72, 25–48, https://doi.org/10.1146/
annurev-micro-022618-042458 (2018).
 26. Nazari, B. et al. Nonomuraea sp. ATCC 55076 harbours the largest actinomycete chromosome to date and the kistamicin 
biosynthetic gene cluster. MedChemComm 8, 780–788, https://doi.org/10.1039/c6md00637j (2017).
1 2Scientific RepoRtS |         (2020) 10:6200  | https://doi.org/10.1038/s41598-020-63257-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 27. Gonsior, M. et al. Biosynthesis of the Peptide Antibiotic Feglymycin by a Linear Nonribosomal Peptide Synthetase Mechanism. 
Chembiochem: a European journal of chemical biology 16, 2610–2614, https://doi.org/10.1002/cbic.201500432 (2015).
 28. Naruse, N., Oka, M., Konishi, M. & Oki, T. New antiviral antibiotics, kistamicins A and B. II. Structure determination. The Journal 
of antibiotics 46, 1812–1818, https://doi.org/10.7164/antibiotics.46.1812 (1993).
 29. Naruse, N. et al. New antiviral antibiotics, kistamicins A and B. I. Taxonomy, production, isolation, physico-chemical properties and 
biological activities. The Journal of antibiotics 46, 1804–1811, https://doi.org/10.7164/antibiotics.46.1804 (1993).
 30. Vertesy, L. et al. Feglymycin, a novel inhibitor of the replication of the human immunodeficiency virus. Fermentation, isolation and 
structure elucidation. The Journal of antibiotics 52, 374–382, https://doi.org/10.7164/antibiotics.52.374 (1999).
 31. Kilian, R., Frasch, H. J., Kulik, A., Wohlleben, W. & Stegmann, E. The VanRS Homologous Two-Component System VnlRSAb of the 
Glycopeptide Producer Amycolatopsis balhimycina Activates Transcription of the vanHAXSc Genes in Streptomyces coelicolor, but 
not in A. balhimycina. Microbial drug resistance 22, 499–509, https://doi.org/10.1089/mdr.2016.0128 (2016).
 32. Foulston, L. & Bibb, M. Feed-forward regulation of microbisporicin biosynthesis in Microbispora corallina. Journal of bacteriology 
193, 3064–3071, https://doi.org/10.1128/JB.00250-11 (2011).
 33. Stegmann, E., Frasch, H. J., Kilian, R. & Pozzi, R. Self-resistance mechanisms of actinomycetes producing lipid II-targeting 
antibiotics. International journal of medical microbiology: IJMM 305, 190–195, https://doi.org/10.1016/j.ijmm.2014.12.015 (2015).
 34. Alduina, R. et al. Expression in Streptomyces lividans of Nonomuraea genes cloned in an artificial chromosome. Applied 
microbiology and biotechnology 68, 656–662, https://doi.org/10.1007/s00253-005-1929-y (2005).
 35. Giardina, A. et al. Two heterologously expressed Planobispora rosea proteins cooperatively induce Streptomyces lividans 
thiostrepton uptake and storage from the extracellular medium. Microbial cell factories 9, 44, https://doi.org/10.1186/1475-2859-9-
44 (2010).
 36. Alt, S. et al. Toward Single-Peak Dalbavancin Analogs through Biology and Chemistry. ACS Chem Biol 14, 356–360, https://doi.
org/10.1021/acschembio.9b00050 (2019).
 37. Gust, B., Challis, G. L., Fowler, K., Kieser, T. & Chater, K. F. PCR-targeted Streptomyces gene replacement identifies a protein domain 
needed for biosynthesis of the sesquiterpene soil odor geosmin. Proc Natl Acad Sci USA 100, 1541–1546, https://doi.org/10.1073/
pnas.0337542100 (2003).
 38. Donadio, S., Monciardini, P. & Sosio, M. Chapter 1. Approaches to discovering novel antibacterial and antifungal agents. Methods in 
enzymology 458, 3–28, https://doi.org/10.1016/S0076-6879(09)04801-0 (2009).
 39. Gonzalez-Quinonez, N. et al. New PhiBT1 site-specific integrative vectors with neutral phenotype in Streptomyces. Applied 
microbiology and biotechnology 100, 2797–2808, https://doi.org/10.1007/s00253-015-7271-0 (2016).
 40. Russo, M. et al. Binding abilities of polyaminocyclodextrins: polarimetric investigations and biological assays. Beilstein journal of 
organic chemistry 13, 2751–2763, https://doi.org/10.3762/bjoc.13.271 (2017).
 41. Rubino, S. et al. Synthesis, structural characterization, anti-proliferative and antimicrobial activity of binuclear and mononuclear 
Pt(II) complexes with perfluoroalkyl-heterocyclic ligands. Inorg Chim Acta 483, 180–190, https://doi.org/10.1016/j.ica.2018.07.039 
(2018).
 42. Blin, K. et al. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic acids research 47, W81–W87, 
https://doi.org/10.1093/nar/gkz310 (2019).
 43. Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Molecular 
biology and evolution 33, 1870–1874, https://doi.org/10.1093/molbev/msw054 (2016).
 44. MacNeil, D. J. et al. Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration 
vector. Gene 111, 61–68, https://doi.org/10.1016/0378-1119(92)90603-m (1992).
 45. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc 
Natl Acad Sci USA 97, 6640–6645, https://doi.org/10.1073/pnas.120163297 (2000).
Acknowledgements
The authors thank Marta Aronica, Letizia Lo Grasso and Andrea Sabella (University of Palermo, Dep. STEBICEF) 
for their laboratory assistance and Anna Maria Puglia for precious discussion.
Author contributions
R.A. conceived, designed the work and wrote the manuscript. A.T. performed resistance assays and glycopeptide 
induction experiments, S.C. and C.F. performed transcriptional analysis and EMSA, P.C. performed protein 
analysis, M.S. carried out LC-MS analysis, S.D. performed bioinformatics analysis and wrote the manuscript. All 
authors contributed to the critical discussion of the manuscript, read and approved the final manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63257-4.
Correspondence and requests for materials should be addressed to R.A.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
